Navigation Links
Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
Date:8/20/2007

... with Sales Team Forming and Increased Space, Poised for Market Launch

KIRKLAND, Wash., Aug. 20 /PRNewswire/ -- Pathway Medical Technologies, Inc., which is developing innovative devices for the treatment of arterial disease, today announced that it has hired a VP of Sales, Joseph W. Rafferty, and has started building its sales team in preparation for the introduction of its first product, Pathway PV(TM) Atherectomy System.

Recently Pathway moved from its old 10,000-square-foot facility to a new state-of-the art 51,000-square-foot, cGMP (Good Manufacturing Practices) - compliant manufacturing facility at 10801 120th Ave NE in Kirkland. The new facility boasts a 6,500-square-foot clean room to meet anticipated market demand. Additional 3000-square-feet are available for future expansion purposes. In the last six months the company's staff has grown from 53 to 91, almost doubling the size of the company, and Pathway continues to add employees to prepare for its first product introduction.

Mr. Rafferty, who will be working out of the company's new headquarters, joins the Pathway executive team with more than 25 years of experience in the medical-device industry. He has held senior sales and marketing management positions at companies like ACS/Guidant, where his contributions led to its leadership position in interventional cardiology. In his role as the Midwest Region Sales Manager, he pioneered Guidant's highly successful P3 (price-per- procedure) program, which ultimately redefined the reimbursement model for interventional cardiology.

"Joe brings extensive field sales, sales management and operational management experience to our team. He will be a significant contributor to the success of Pathway's premier new product. He knows how to build a leading sales organization for a category leader," said Pathway CEO and President Tom Clement.

"When you have a product about to launch with all the hallmarks of a category leader, it's ex
'/>"/>

SOURCE Pathway Medical Technologies, Inc.

Copyright©2007 PR Newswire.

1

GOOD

Page: 1 2

Related biology technology :

1. Assess the In Vivo Activation of Signal Transduction Pathways with PathDetect Reporting Systems
2. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
3. In Vivo Signal Transduction Pathway Reporting Systems
4. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
5. New Fusion Trans-Activator Plasmids for Studying Signal Transduction Pathways
6. Medical College receives $377K to study brain disease
7. Barriers will not stop convergence of medical technologies
8. Medical College team creates website for tracking flu
9. Biomedical engineering conference invites manufacturers
10. Visions: Wade offers straight talk on e-medical records
11. Merge unveils updated medical imaging software

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...v. 20 Novavax, Inc. (Nas... underwritten public offering of 6,800,000 shares ....30 per share. The approximately $21 million of n...ounts and commissions, will be used for preclinica...cines, internal research and development programs,...
(Date:11/19/2009)...e able to charge their cell phones and other perso...t discovery made by UC San Diego engineers could l...could do just this. , In recent research, publi...ru, a professor in the UCSD Department of Mechanic...student Mark Hoefer, have found that artificially ...
(Date:11/19/2009)...RNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: ...wing letter to its shareholders, discussing the Co... Biopharmaceuticals Holdings, Inc. (CHBP), an inte...ple,s Republic of China. The merger gives NeoStem ...utical Co. Ltd., CHBP,s primary operating subsidia...
(Date:11/19/2009)...ASIK surgeons and recognized refractive and catara...s made brought their fellow surgeons up-to-date on...ery, cataract surgery, and ophthalmology in genera...hthalmology (AAO) annual meeting in San Francisco,...uber, Dr. David Huang, MD, Dr. Randy Epstein, Dr. ...
Breaking Biology Technology:Novavax Prices Public Offering of Common Stock 2Nanotube defects equal better energy and storage systems 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 2Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 3Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 4Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 5Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 6Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 7Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 8Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 9
.... today,announced it has secured $20 million in ve...ed the syndicate, which includes Silicon Valley Ba...ion from the financing line,at closing. The remain...of,corporate milestones., "This financing reflect...nd our clinical programs," said Mark Perry, Aerova...
... Which will Commence the Marketing of Res...ASKING RIDGE, N.J., March 28 Millennium,Biotechno...um,Biotechnologies Group, Inc. (MBTG) announced to... and letter of credit associated with the recently...c. of Canada. Ferring,Inc. will commence the marke...
...Nasdaq: VICL ) today announced the company,s lice...27, 2008, of a New Drug Application (NDA) to,the J...its angiogenesis,product candidate, Collategene, f...ent uses Vical technology to deliver a gene encodi... that causes growth of blood vessels in,areas of r...
Other Biology Technology:Ferring Initial Purchase Order and Guaranteed Letter of Credit Launches Five Year Contract 2Ferring Initial Purchase Order and Guaranteed Letter of Credit Launches Five Year Contract 3Vical Licensee AnGes MG Files NDA in Japan for Collategene Angiogenesis Product 2Vical Licensee AnGes MG Files NDA in Japan for Collategene Angiogenesis Product 3Vical Licensee AnGes MG Files NDA in Japan for Collategene Angiogenesis Product 4
(Date:11/22/2009)...ited gene deletion can increase the likelihood of ...antation, an international team of researchers rep...ature Genetics . When the gene, called UGT2B17, is...e recipient,s, transplants have a significantly gr...-versus-host disease, in which immune cells from t...
(Date:11/22/2009)...e Brain Research Centre, a partnership of the Univ... Vancouver Coastal Health Research Institute, have...which brain cells die following a stroke, as well ...ults of the study were recently published online i...brain cells continue to die even after blood flow ...
(Date:11/20/2009)...port published in the November 2009 issue of the j...entists show how a family of genes (1-aminocyclopr...sponsible for production of ethylene. This gas aff...nformation lays the foundation for future genetic ...ant, able to survive and thrive in difficult terra...
Breaking Biology News(10 mins):Gene mismatch influences success of bone marrow transplants 2Gene mismatch influences success of bone marrow transplants 3Gene mismatch influences success of bone marrow transplants 4New understanding about mechanism for cell death after stroke leads to possible therapy 2It's a gas: New discovery may lead to heartier, high-yielding plants 2Offits Failure to Disclose Jeopardizes Swine Flu Vaccine Program 56353 1Offits Failure to Disclose Jeopardizes Swine Flu Vaccine Program 56353 2Offits Failure to Disclose Jeopardizes Swine Flu Vaccine Program 56353 3Frost 26 Sullivan Global Heart Health Ingredients Excellence in Financial 26 Risk Management Award Conferred on Pronova BioPharma 56352 1Frost 26 Sullivan Global Heart Health Ingredients Excellence in Financial 26 Risk Management Award Conferred on Pronova BioPharma 56352 2Frost 26 Sullivan Global Heart Health Ingredients Excellence in Financial 26 Risk Management Award Conferred on Pronova BioPharma 56352 3Frost 26 Sullivan Global Heart Health Ingredients Excellence in Financial 26 Risk Management Award Conferred on Pronova BioPharma 56352 4Frost 26 Sullivan Global Heart Health Ingredients Excellence in Financial 26 Risk Management Award Conferred on Pronova BioPharma 56352 5United States Patent and Trademark Office Publishes Stemedica 26apos 3Bs Patent Application for the Treatment of Diabetic Retinopathy 13878 1United States Patent and Trademark Office Publishes Stemedica 26apos 3Bs Patent Application for the Treatment of Diabetic Retinopathy 13878 2United States Patent and Trademark Office Publishes Stemedica 26apos 3Bs Patent Application for the Treatment of Diabetic Retinopathy 13878 3
...e discovered the earliest form of human,blood stem... embryonic,stem cells replicate and grow. They al...ints these stem cells, which serve as the progenit...ochemical marker, angiotensin-converting enzyme (A...of blood pressure, blood vessel,growth, and inflam...
...s number one feed grain and a staple food for many...ce increases that are forecast to continue over th...w temperatures could be overcome, then the length ...ed at present sites of cultivation and its range e...Archie Portis, Steve Moose, and Steve Long in the ...
...cancerous mainly because they lose control of thei... new study at Ohio State University,s Comprehensiv...late cell growth in embryos and that contribute to...f3a and E2f3b are generally believed to work toge...that comes from experiments using only cells. Canc...
Other Biology News:Researchers devise means to create blood by identifying earliest stem cells 2Researchers devise means to create blood by identifying earliest stem cells 3Key discovered to cold tolerance in corn 2Location, location, location important for genes, too 2
MUTAN SUPER EXPRESS KM 20 RXN from Takara Mirus Bio
...the 9, 10, 12, and 13 positions. It is intended fo...on of 13(S)-HODE by GC- or LC-mass spectrometry. 1...id with plant and mammalian lipoxygenases. It has ...to the endothelium at concentrations around 1 �...
... are recommended for protein expression from pTriE...tion has been selected based on rapid, vigorous ce...ved specifically with baculoviruses derived from t...-Plaque Sf9 Cells and BacVector Insect Cell Medium...
Adaptor BamH I-Sma I from Takara Mirus Bio
Biology Products: